Drug Trial Radar · NCT05621811
Different Doses of Naronapride vs. Placebo in Gastroparesis
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
328
Actual
Start
Jan 3, 2023
Primary completion
Aug 12, 2025
Study completion Sep 4, 2025
Sponsor
- Lead sponsor
- Dr. Falk Pharma GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
Conditions
- Gastroparesis
Interventions
NaronaprideDrug
Naronapride is a gut lumen active, bifunctional 5HT-4 agonist//D2 antagonist
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary Total Score at Week 12Time frame: Baseline and Week 12
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Dr Falk Investigational Site
Chula Vista, California
Dr Falk Investigational Site
Lomita, California
Dr Falk Investigational Site
Clearwater, Florida
Dr Falk Investigational Site
Doral, Florida
Dr Falk Investigational Site
Hollywood, Florida
Dr Falk Investigational Site
Maitland, Florida
Dr Falk Investigational Site
Miami, Florida
Dr Falk Investigational Site
Miami, Florida
Dr Falk Investigational Site
Viera, Florida
Dr Falk Investigational Site
Kansas City, Kansas
Dr Falk Investigational Site
Topeka, Kansas
Dr Falk Investigational Site
Crestview Hills, Kentucky
Dr Falk Investigational Site
Houma, Louisiana
Dr Falk Investigational Site
Marrero, Louisiana
Dr Falk Investigational Site
Flint, Michigan
Dr Falk Investigational Site
Flint, Michigan
Dr Falk Investigational Site
New York, New York
Dr Falk Investigational Site
Cleveland, Ohio
Dr Falk Investigational Site
Tulsa, Oklahoma
Dr Falk Investigational Site
Philadelphia, Pennsylvania
Dr Falk Investigational Site
Cordova, Tennessee
Dr Falk Investigational Site
Nashville, Tennessee
Dr Falk Investigational Site
Harlingen, Texas
University of Leuven
Leuven, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.